Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications
The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | ONIX_20210501_9783039360345_434 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869521413150343168 |
|---|---|
| collection | Directory of Open Access Books |
| description | The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells. |
| format | Online |
| id | doab-20.500.12854ir-68688 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-686882024-03-30T23:22:50Z Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications Ishii, Kenichiro androgen receptor docetaxel cabazitaxel castration-resistant prostate cancer chemotherapy P-glycoprotein EPI-002 splice variant prostate-specific antigen androgen deprivation therapy time to PSA nadir fibroblasts prostate cancer androgen sensitivity pirfenidone TGFβ1 G1 cell cycle arrest fibroblast growth factor fibroblast growth factor receptor obesity inflammation immune cells cytokine high-fat diet KIFC1 docetaxel resistance apoptosis CW069 Caveolin-1 TP53-regulated inhibitor of apoptosis 1 tumour stroma tumour microenvironment fibroblast CAF resistance radiotherapy CCL2 CCL22 CCL5 migration LSD1 epigenetics autophagy abiraterone enzalutamide testosterone castration resistant prostate cancer animal model diet fat in vitro in vivo mouse AKR1C3 hormone-naïve prostate cancer immunohistochemistry tissue microarray androgen receptor dependency fibroblast-dependent androgen receptor activation n/a thema EDItEUR::M Medicine and Nursing The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells. 2021-05-01T15:26:53Z 2021-05-01T15:26:53Z 2020 book ONIX_20210501_9783039360345_434 9783039360345 9783039360352 https://directory.doabooks.org/handle/20.500.12854/68688 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2453 https://mdpi.com/books/pdfview/book/2453 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03936-035-2 10.3390/books978-3-03936-035-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039360345 9783039360352 184 Basel, Switzerland open access |
| spellingShingle | androgen receptor docetaxel cabazitaxel castration-resistant prostate cancer chemotherapy P-glycoprotein EPI-002 splice variant prostate-specific antigen androgen deprivation therapy time to PSA nadir fibroblasts prostate cancer androgen sensitivity pirfenidone TGFβ1 G1 cell cycle arrest fibroblast growth factor fibroblast growth factor receptor obesity inflammation immune cells cytokine high-fat diet KIFC1 docetaxel resistance apoptosis CW069 Caveolin-1 TP53-regulated inhibitor of apoptosis 1 tumour stroma tumour microenvironment fibroblast CAF resistance radiotherapy CCL2 CCL22 CCL5 migration LSD1 epigenetics autophagy abiraterone enzalutamide testosterone castration resistant prostate cancer animal model diet fat in vitro in vivo mouse AKR1C3 hormone-naïve prostate cancer immunohistochemistry tissue microarray androgen receptor dependency fibroblast-dependent androgen receptor activation n/a thema EDItEUR::M Medicine and Nursing Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title | Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title_full | Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title_fullStr | Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title_full_unstemmed | Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title_short | Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
| title_sort | cytobiology of human prostate cancer cells and its clinical applications |
| topic | androgen receptor docetaxel cabazitaxel castration-resistant prostate cancer chemotherapy P-glycoprotein EPI-002 splice variant prostate-specific antigen androgen deprivation therapy time to PSA nadir fibroblasts prostate cancer androgen sensitivity pirfenidone TGFβ1 G1 cell cycle arrest fibroblast growth factor fibroblast growth factor receptor obesity inflammation immune cells cytokine high-fat diet KIFC1 docetaxel resistance apoptosis CW069 Caveolin-1 TP53-regulated inhibitor of apoptosis 1 tumour stroma tumour microenvironment fibroblast CAF resistance radiotherapy CCL2 CCL22 CCL5 migration LSD1 epigenetics autophagy abiraterone enzalutamide testosterone castration resistant prostate cancer animal model diet fat in vitro in vivo mouse AKR1C3 hormone-naïve prostate cancer immunohistochemistry tissue microarray androgen receptor dependency fibroblast-dependent androgen receptor activation n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | androgen receptor docetaxel cabazitaxel castration-resistant prostate cancer chemotherapy P-glycoprotein EPI-002 splice variant prostate-specific antigen androgen deprivation therapy time to PSA nadir fibroblasts prostate cancer androgen sensitivity pirfenidone TGFβ1 G1 cell cycle arrest fibroblast growth factor fibroblast growth factor receptor obesity inflammation immune cells cytokine high-fat diet KIFC1 docetaxel resistance apoptosis CW069 Caveolin-1 TP53-regulated inhibitor of apoptosis 1 tumour stroma tumour microenvironment fibroblast CAF resistance radiotherapy CCL2 CCL22 CCL5 migration LSD1 epigenetics autophagy abiraterone enzalutamide testosterone castration resistant prostate cancer animal model diet fat in vitro in vivo mouse AKR1C3 hormone-naïve prostate cancer immunohistochemistry tissue microarray androgen receptor dependency fibroblast-dependent androgen receptor activation n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20210501_9783039360345_434 |